Nifedipine in pregnancy

Smith, Patricia; Anthony, John; Johanson, Richard

doi:10.1111/j.1471-0528.2000.tb13222.x

Cited by 75 publications

(34 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dhawle et al found it to be 35 days in his study. 12 Smith et al observed prolongation around 35.2 days. 13 Nifedipine prolonged pregnancy beyond two days in 80.9 % women and beyond 7 days in 72.1 % cases in a study by Papatsonis et al, whereas, Kashanian et al found the pregnancy prolongation beyond two days to be 75 % and beyond 7 days in 65 % women.…”

Section: Discussionmentioning

confidence: 99%

Our experience of nifedipine as a tocolytic agent in preterm labor (24 weeks to 36 weeks 6 days)

Hangekar

Karale

Risbud

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Preterm birth is defined as birth between the age of viability and 37 completed weeks of gestation. The aim of this study is to evaluate the safety and efficacy of nifedipine, a calcium channel blocker, as a tocolytic in prolonging duration of pregnancy in case of preterm labor.Methods: This is a retrospective analytical study conducted in Department of Obstetrics and Gynaecology, SKNMC and GH, Pune, India conducted over a period of one year from June 2014 to May 2015. All uncomplicated, singleton preterm labor cases were given Cap. Nifedipine as tocolytic and Inj. Betamethasone for enhancing fetal lung maturity. Maternal parameters studied were Gravida and Parity, previous history of preterm labor, gestational age at delivery, mode of delivery, side effects. Neonatal parameters studied were weight at birth, APGAR score at birth, complications at birth, NICU admissions, mortality.Results: Out of total 4478 deliveries from June 2014 to May 2015, 252 women with preterm labor were treated with nifedipine. 214 out of 252 delivered at term with overall success rate of 84.92%. Out of remaining 38 cases, 36 cases delivered as preterm normal deliveries and 2 required Caesarean section. No major side effects observed in mothers receiving nifedipine. As regards neonatal outcome, 12 babies required NICU admission and mortality was of 2.Conclusions: Nifedipine is safe and effective in prolonging preterm labor and has minimal maternal and neonatal side effects. It eliminates the need for intensive maternal monitoring as required in case of betamimetics.

show abstract

Section: Discussionmentioning

confidence: 99%

Our experience of nifedipine as a tocolytic agent in preterm labor (24 weeks to 36 weeks 6 days)

Hangekar

Karale

Risbud

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…A notable decrease in vascular resistance occurs, whereas the venous system is unaffected [5]. Calcium channel blockers of the dihydropyridine family cause arterial vasodilatation in pregnant hypertensive women, but administrating them to patients with normal blood volume does not significantly change arterial pressure [3]. Therefore it is possible to administer a high dose of a calcium channel blocker without causing arterial hypotension.…”

Section: Pharmacologic Effectsmentioning

confidence: 98%

“…They act on the calcium channels and block the entry of extracellular calcium into the cell, thereby inhibiting contractions of smooth muscle cells [3].…”

Section: Calcium Channel Blockersmentioning

confidence: 99%

New tocolytic agents

Tayeh

Tsatsaris

Goffinet

et al. 2005

Eur Clinics Obstet Gynecol

View full text Add to dashboard Cite

Prematurity has not decreased significantly over the past 20 years, whereas early prematurity has increased. New tocolytic agents have been developed that are increasingly successful at preventing preterm delivery, and that have improved maternal tolerance. Although their use is not approved of by European or American drug agencies, calcium channel blockers are currently widely used for tocolysis. Their efficacy and the absence of dangerous side effects on mother and fetus justify their use, even as a first line therapy. Oxytocin antagonists are also widely used. Their effectiveness appears to be similar to that of b-adrenergic agonists, but unlike them oxytocin antagonists are devoid of any measurable side effects. They were designed specifically as tocolytics and have been validated by the European Drug Agency. They have a place in the treatment of preterm labor. New molecules are being investigated; they could possibly be used in the future with greater efficacy.

show abstract

“…La Cochrane Database effectuant une méta-analyse (neuf études incluant 876 patientes) montre un risque relatif pour les inhibiteurs calciques de 0,8 (0,61-1,05) [10]. Elle est également comparable [8,11,[13][14][15][16][17] voire supérieure à celle des bêtami-métiques [12] et ce, à 48 heures comme à sept jours dans d'autres études.…”

Section: Résultatsunclassified